Top 5 Most Read RNS's on Vox Markets for Thursday 6th April 2023

Episode 1317,   Apr 06, 2023, 06:44 AM

Top 5 Most Read RNS's on Vox Markets for Thursday 6th April 2023

5. THG PLC #THG - Notice of FY Results and Q1 Trading Update

THG PLC will publish its results for the year ended 31 December 2022, alongside its trading statement for the first quarter of 2023, on 18 April 2023.

The THG management team will be hosting a conference call and webcast for analysts and investors on 18 April 2023 at 09:00 BST.

4. Hurricane Energy #HUR - Recommended Offer – Meeting for Shareholders

The Company announces that it will be holding a meeting on 18 April 2023 for shareholders, where senior management will provide a presentation relating to the recommended acquisition by Prax Exploration & Production PLC .

This will be followed by a question and answer session where senior management will address questions that shareholders may have.

3. THG PLC #THG - THG Ingenuity announces a strategic partnership

THG PLC announces a new partnership with beauty e-commerce retailer Maximo Group ("Maximo"), home to destination sites including allbeauty.com and fragrancedirect.co.uk.

The 10-year partnership will initially focus on re-platforming All Beauty and Fragrance Direct to the Ingenuity platform, as part of Maximo's strategic growth plans.

The partnership between THG Ingenuity and Maximo Group is expected to add in excess of £150 million GMV to the Ingenuity platform annually, with the ambition to re-platform the site by the end of Q2 2023.

2. Helium One Global #HE1 - Drilling Rig Update

Helium One Global announce that the Company has, alongside Noble Helium (ASX:NHE), entered into a Letter of Intent ("LoI") with Tunisian Drilling Contractor, SOFORI, for the provision of the Drillmec HH102 oil and gas rig for their drilling campaign at Rukwa.

This rig share initiative, following on from the co-operation agreement, will enable the Company to save significant costs on mob/demobilisation.

The Company looks forward to progressing this LoI into a definitive contract.

1. Avacta Group #AVCT - 1st US Clinical Investigator AVA6000 Sites Opened

Avacta Group announces the opening on 5 April 2023 of the first two clinical investigator sites for the phase 1 clinical trial of AVA6000 under its US Investigational New Drug (IND) Application.